Tanshinones induce tumor cell apoptosis via directly targeting FHIT

Xianglian Zhou¹, Yuting Pan¹, Yue Wang¹, Bojun Wang¹, Yu Yan², Yi Qu¹ & Xisong Ke¹∗

The liposoluble tanshinones are bioactive components in *Salvia miltiorrhiza* and are widely investigated as anti-cancer agents, while the molecular mechanism is to be clarified. In the present study, we identified that the human fragile histidine triad (FHIT) protein is a direct binding protein of sodium tanshinone IIA sulfonate (STS), a water-soluble derivative of Tanshinone IIA (TSA), with a Kd value of 268.4 ± 42.59 nM. We also found that STS inhibited the diadenosine triphosphate (Ap3A) hydrolase activity of FHIT through competing for the substrate-binding site with an IC₅₀ value of 2.2 ± 0.05 µM. Notably, near 100 times lower binding affinities were determined between STS and other HIT proteins, including GAL T, DCPS, and phosphodiesterase ENPP1, while no direct binding was detected with HINT1. Moreover, TSA, Tanshinone I (TanI), and Cryptotanshinone (CST) exhibited similar inhibitory activity as STS. Finally, we demonstrated that depletion of FHIT significantly blocked TSA’s pro-apoptotic function in colorectal cancer HCT116 cells. Taken together, our study sheds new light on the molecular basis of the anti-cancer effects of the tanshinone compounds.

The human fragile histidine triad (FHIT) is a tumor suppressor gene located at chromosome region 3p14.2, which inactivated in > 50% human tumors accounting for deletion, mutation, and hypermethylation¹. FHIT is a member of the histidine triad (HIT) family with a conserved histidine triad sequence motif at the N-terminal that are important for the diadenosine triphosphate (Ap3A) binding and hydrolysis²–⁴. Previous studies revealed that re-expression of FHIT in FHIT-negative tumor cells resulted in significant cell proliferation inhibition⁵,⁶. Recent studies showed that the function of FHIT in tumor suppression depends on Ap3A binding⁷,⁸. Because FHIT H96N mutant without hydrolase activity still has anti-tumor functions, while L25W mutant without Ap3A binding activity shows no tumor suppressive function. In line with a tumor suppressor function, FHIT loss increased the migration and invasion capacities of tumor cells⁹–¹¹. Various signaling pathways were altered upon FHIT loss or overexpression, such as NF-κB signaling¹², Ras/Rho GTPase signaling¹³, DNA damage-response checkpoint activation¹⁴, ROS production¹⁵,¹⁶.

A few molecules have been reported to date that are able to inhibit FHIT’s enzymatic activity. Among these, suramin and non-cleavable ApnA analogues have been presented over a decade which inhibit FHIT without selectivity compared to other different classes of enzymes¹⁷,¹⁸. During past year, a high-throughput screening assay of Förster Resonance Energy Transfer (FRET) was developed to discover potent small molecule inhibitors of FHIT based on a doubly labeled Ap3A probe¹⁹, and several inhibitors with methylpyrazolo-motive or indino-motive were identified to block FHIT activity²⁰, but those inhibitors were not applied to cellular content, potentially due to the difference of protein between purified protein and cellular protein with extensive post-translational modification and protein–protein interactions²¹.

*Salvia miltiorrhiza* (SM) is a widely used traditional Chinese medicine in China²². The main active ingredients of SM are liposoluble tanshinone compounds, which mainly include tanshinone IIA (TSA), dihydrotanshinone (DT), tanshinone I (TanI), and cryptotanshinone (CT)²³,²⁴. Among these compounds, TSA has been broadly investigated due to its various biological activities, especially cancer inhibition²⁵–²⁸. Recently, TSA’s anti-cancer activities were connected with induction of apoptosis and autophagy, inhibition of cell growth and migration by regulating AMPK²⁹,³⁰, Notch1/NF-κB³¹, PI3K/Akt/mTOR signaling pathway³², and so on. Sodium tanshinone IIA sulfonate (STS), a water-soluble sulfonate on C-16 position derived from TSA, has been approved to treat cardiovascular diseases for more than a decade³³. Numerous studies demonstrated that the beneficial effects of

¹Center for Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China. ²Shanghai Innovation Center of TCM Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai, China. ³email: yiqu@shutcm.edu.cn; xisongke@shutcm.edu.cn
STS in various diseases are attributable to its role in reducing reactive oxygen species (ROS) production and decreasing pro-inflammatory cytokines34–38.

Here, we report that STS directly engaged to FHIT protein and inhibited FHIT Ap3A hydrolase activity through the competitive binding to the FHIT substrate binding site. Similar effects were observed with other tanshinone analogs, including TSA, TanI, and CST, although STS and TSA were very different on cell toxicity. Finally, we demonstrated that FHIT depletion partially blocked the pro-apoptotic function of TSA.

Results

STS directly binds to FHIT protein. To identify small molecule directly binding to FHIT in cellular content, we took the advantage of microscale thermophoresis (MST) assay that allows determining the direct engagement between small molecule and cellular target proteins in biological liquid39,40. We first created HEK293T cells containing GFP-tagged FHIT and prepared the cell lysates for single-point MST binding check screening. In a FDA-approved drug library containing 1971 compounds, several small molecules were found directly binding to FHIT (Fig. 1). Among these candidates, MST binding affinity check assay revealed small molecule with the highest binding affinity is STS, a water-soluble derivative of TSA, and the Kd value between STS and FHIT was 268.4 ± 42.59 nM (Fig. 2B). To further verify the direct interaction between STS and FHIT, we purified FHIT protein in E.coli. Interestingly, we also detected a binding curve using the purified FHIT, but the binding affinity (Kd value = 1.82 ± 0.3 µM) was 5 times lower that the cellular FHIT (Fig. 2B). The higher binding affinity of cellular FHIT and STS supports the advantage of drug screening using cellular protein.

STS binds to the FHIT substrate-binding site. The overall structure of FHIT is displayed as a general α + β type, and the N terminal is the HIT domain which accounts for Ap3A binding and hydrolysis (Fig. 2C). The FHIT protomer contains two helices, A and B, and seven β strands41. Substrate binds on the surface of the pocket consisted of seven β strands in the crystal structure of the FHIT-IB2 complex7. To determine the binding site of STS, we constructed three GFP-tagged FHIT truncations (Fig. 2C). In cellular MST assay, robust binding curve was determined with STS and truncation region 1 (TR1) and TR2, but no direct binding was observed with TR3, which represented C-terminal only (Fig. 2D). The occupation of STS to the HIT domain implies that STS potentially attaches to the substrate-binding pocket of FHIT. To validate the possibility, molecule docking was proposed to assess the interaction between STS and FHIT using the published crystal structure of the FHIT-AMP complex [Protein Data Bank (PDB): 3FIT]. Indeed, the prediction showed that STS adopts a similar three-dimensional (3D) conformation upon docking to FHIT as AMP (Fig. 2E). Moreover, STS could be well fitted into the ‘active site’ of FHIT in the surface model (Fig. 2F).

STS competitively inhibits FHIT hydrolase activity. Next, we attempted to assess whether STS inhibits its hydrolase activity of FHIT. It has been established that Ap3A can be rapidly hydrolyzed to AMP and ADP by FHIT4. Therefore the production of ADP in the reaction system could represent the hydrolase activity of FHIT. With this principle, we determined the IC50 value of suramin (a known inhibitor of FHIT) is 0.26 ± 0.08 µM, which was comparable to previous report17. Using the same method, we found that STS inhibits the hydrolase activity of FHIT with an IC50 value of 0.34 ± 0.09 µM (Fig. 3A). To further investigate whether STS inhibits FHIT hydrolase activity via competitive engagement with the substrate-binding site of FHIT, we purified an FHIT mutant that substituted His to Asn at the central histidine (H96N mutant), which is catalytically inactive with no effect on substrate binding7,8. Consistently, in a fluorescence polarization assay with the H96N mutant utilizing a fluorogenic substrate ApppBODIPY, STS significantly disrupted the interaction between H96N mutant and ApppBODIPY with an IC50 value of 2.2 ± 0.05 µM (Fig. 3B). Similar result was observed for suramin with an IC50 value of 2.6 ± 0.044 µM (Fig. 3B). All those results indicated that STS is a competitive inhibitor for FHIT.
STS binds to HIT family proteins with increased Kd values and inhibits ENPP1 hydrolase activity at higher concentration. Totally there are seven HIT proteins and classified into five branches according to their structure and functions in humans42. To investigate the selectivity of STS to those HIT proteins, we purified other three HIT proteins, HINT1, DCPS, and GALT. It was reported that ENPP1 rapidly hydrolyzed Ap3A into ADP and AMP, thereby regulating the function of platelet43. As expected, direct binding was also observed between STS and ENPP1, although different binding affinities were detected for those HIT proteins and ENPP1, for examples, the Kd value for DCPS is 9.31 ± 0.4 µM, for GALT is 12.92 ± 0.54 µM, for ENPP1 is 27.22 ± 1.96 µM (Fig. 4A). Notably, no direct binding curve was observed between STS and HINT1 (Fig. 4A).

We also tested whether STS inhibits Ap3A hydrolyze activity of ENPP1. In the same method of Ap3A hydrolysis assay, we performed MST assay of STS and GFP tagged FHIT truncations. The Kd value is 75.05 µM for TR1 (blue circle), and 58.18 µM for TR2 (blue square). No Kd value was calculated with TR3 (dull-red triangle). (E) Representation of molecule docking of FHIT-STS complex by Autodock vina software based on the FHIT-AMP complex (PDB code:3FIT). The region of 1-43aa is shown in mazarine, 44-108aa is shown in wathet, 109-147aa is shown in red. STS is shown in green sticks and AMP is shown in purple sticks. Structure alignment indicated that STS almost occupies the AMP binding site. (F) The surface model of the predicated FHIT-STS complex.

Figure 2. STS directly binds to FHIT protein. (A) Chemical structure of STS. (B) Cellular MST assay of the interaction between STS and FHIT. HEK293T cell lysate containing GFP tagged FHIT (black circle) or Red-NHS labeled FHIT (red square) were incubated with STS. The Kd value is 268.4 ± 42.59 nM and 1.82 ± 0.3 µM for GFP-FHIT and Red-NHS FHIT, respectively. (C) Schematic representation of the full-length FHIT and the truncated mutants used in the MST assay. The N-terminal region (1-108aa) containing the HIT domain is colored by blue, and the C terminal is colored by red. (D) MST assay of STS and GFP tagged FHIT truncations, the Kd value is 75.05 µM for TR1 (blue circle), and 58.18 µM for TR2 (blue square). No Kd value was calculated with TR3 (dull-red triangle). (E) Representation of molecule docking of FHIT-STS complex by Autodock vina software based on the FHIT-AMP complex (PDB code:3FIT). The region of 1-43aa is shown in mazarine, 44-108aa is shown in wathet, 109-147aa is shown in red. STS is shown in green sticks and AMP is shown in purple sticks. Structure alignment indicated that STS almost occupies the AMP binding site. (F) The surface model of the predicated FHIT-STS complex.
lase activity detection as described above (Fig. 3A), STS showed much less inhibition to ENPP1 compared to suramin (Fig. S1B). This was confirmed by the thin layer chromatography (TLC) assay with ApppBODIPY, in that suramin inhibited ENPP1 hydrolase activity at 6.25 µM, whereas STS did not show inhibition until to 125 µM (Fig. S1C). Altogether, These results indicate that STS specifically inhibits FHIT hydrolase activity compared with ENPP1. The inhibition of STS on the enzyme activity of DCPS and GALT needs further investigation.

Figure 3. STS inhibits FHIT hydrolase activity through occupation of FHIT substrates binding pocket. (A) STS significantly inhibited FHIT Ap3A hydrolase activity (black square) with IC50 = 0.34 ± 0.09 µM, the IC50 of suramin (red circle) was 0.26 ± 0.08 µM. (B) In fluorescence polarization assay, the IC50 was 2.2 ± 0.05 µM for STS (black square) and FHIT H96N-ApppBODIPY binding inhibition, and the IC50 was 2.6 ± 0.044 µM for suramin (red circle).

Figure 4. Selectivity assay of the binding between STS and FHIT. (A) The binding affinity determination between STS and purified HIT family proteins by MST, and the Kd value was 9.31 ± 0.4 µM for DCPS (orange circle), 12.92 ± 0.54 µM for GALT (celadon square), and 27.22 ± 1.96 µM for ENPP1 (pink inverted triangle). No binding affinity was calculated with HINT1 (light green triangle). FHIT (blue rhombus) was used as a control. (B) MST assay of the binding between tanshinone compounds and FHIT, the Kd value is 112 ± 27.3 nM for TSA (blue square), 466 ± 60 nM for TanI (purple triangle), and 123 ± 31.7 nM for CST (green inverted triangle). STS (orange circle) was used as a control.
STS analogs inhibit FHIT enzyme activity. There are two other tanshinone compounds TanI and CST with similar biological effects as TSA, the major bioactive compound of Danshen44. Moreover, the structures of these three compounds are very similar, except that CST has a single bond at the C-15 position of the furan ring and TanI having a methylbenzene instead of dimethyl cyclohexanes at the left compared with TSA (Fig. 5A). To investigate whether these three compounds inhibit FHIT hydrolase activity or not, we firstly determined the binding affinity between those compounds and FHIT via MST assay. As expected, all the compounds displayed similar binding curves with the Kd value around 100–150 nM except TanI (Fig. 4B). The Kd value of TanI increased by four-folds (466 ± 60 nM), which may be due to the different structure of TanI at the left compared with others. Furthermore, in TLC assay with ApppBODIPY45, TSA, TanI, and CST exhibited similar inhibition on FHIT hydrolase activity with IC50 values of 4 ~ 6 µM, and STS displayed slightly more effective inhibition than others (Fig. 5B).

The effect of TSA inducing tumor cell apoptosis is blocked by FHIT depletion. It has been reported that the FHIT-Ap3A complex may mediate the anti-tumor function of FHIT by inducing apoptosis7,8. To investigate whether tanshinone compounds inhibit tumor cell growth via FHIT-dependent apoptosis pathway, we created FHIT knockout (KO) colorectal HCT116 cells by CRISPR/Cas9 mediated genome editing, genomic DNA sequence revealed that exon5 to exon6 of the FHIT gene was deleted (Fig. S2A), and the depletion of FHIT protein was confirmed by western blotting (Fig. S2B). In ordinary culture, no clear change of FHIT knockout cells was observed regarding the epithelial morphology and growth rate compared to wild-type (WT) cells (Fig. S2D). Next, we determined the cytotoxicity of STS and TSA in WT HCT116 cells. CCK8 assay shown STS had no cytotoxicity, even the concentration is as high as 100 µM (Fig. S3A). TSA significantly inhibits the growth of HCT116 cells at 2 µM (Fig. S3A). A previous study reported that TSA, TanI, and CST induced tumor cell apoptosis46. To ask if FHIT knockout disrupt the pro-apoptotic effects of TSA and TanI, apoptosis was detected by flow cytometry with Annexin V-fluorescein isothiocyanate (V-FITC) and propidium iodide (PI) staining. When cells were treated with 5 µM TSA for 24 h, the apoptosis rate (4.9%) in FHIT KO cells was significantly lower than the rate (13.5%) in WT cells (Fig. 6A). Similar to previous report15, when cells were treated with camptothecin (CPT) at 1 µM that served as a positive control, apoptosis was significantly lower in KO cells (5.3%) than in WT cells (24.9%) as well (Fig. 6C). Notably, TanI led more striking difference in apoptosis assay between WT and KO cells, in that TanI at 10 µM induced 31.66% apoptosis in WT cells and 12.7% apoptosis cells in KO cells (Fig. 6B), a significant difference was also presented at 5 µM (Fig. 6D). All these findings indicated that tanshinone compounds induction of tumor cell apoptosis is partially dependent on FHIT.

Figure 5. Tanshinone compounds inhibit FHIT Ap3A hydrolase activity. (A) Chemical structure of Tanshinone IIA (left), Tanshinone I (middle), and Cryptotanshinone (right). (B) Fluorescent thin layer enzyme assay, significant inhibition activity was detected in all the tanshinone compounds with IC50 value at ~ 5 µM.

| STS(μM) | ApppBODIPY | BODIPY |
|---------|------------|--------|
| 100 | 50 | 25 | 12.5 | 6.25 | 3.13 | 1.56 | 0.78 | 0.39 | 0.2 |
| Negative control | Positive control |

| TSA(μM) | ApppBODIPY | BODIPY |
|---------|------------|--------|
| 100 | 50 | 25 | 12.5 | 6.25 | 3.13 | 1.56 | 0.78 | 0.39 | 0.2 |
| Negative control | Positive control |

| TanI(μM) | ApppBODIPY | BODIPY |
|---------|------------|--------|
| 100 | 50 | 25 | 12.5 | 6.25 | 3.13 | 1.56 | 0.78 | 0.39 | 0.2 |
| Negative control | Positive control |

| CST(μM) | ApppBODIPY | BODIPY |
|---------|------------|--------|
| 100 | 50 | 25 | 12.5 | 6.25 | 3.13 | 1.56 | 0.78 | 0.39 | 0.2 |
| Negative control | Positive control |
Figure 6. TSA inhibition cell growth is partially dependent on FHIT. Flow cytometry assay of apoptosis analysis for TSA (A) and TanI (B). FHIT WT and KO HCT116 cells were treated with the indicated concentrations of ligand for 24 h, then cells were stained for PI and Annexin V before flow cytometry analysis. (C) Qualification of V-FITC/PI measurements of apoptotic cells in (A). The experiment was repeated three times in each group. Data were analyzed using two-way ANOVA, one asterisk stands for P < 0.05, four asterisks stand for P < 0.0001. (D) Quantification of V-FITC/PI positive apoptotic cells in (B). The experiment was repeated 3 times in each group. Data were analyzed using two-way ANOVA, two asterisks stand for P < 0.001, three asterisks stand for P < 0.0005.
Discussion

Tanshinones are natural terpenoids and the main bioactive ingredients of Salvia miltiorrhiza23,24. Previous studies showed that tanshinones inhibit tumor via induction of various apoptosis signaling pathways46. Our study demonstrated that tanshinone compounds directly bind to FHIT and inhibit the hydrolase activity. We found that STS is a competitive inhibitor of FHIT by occupying the active site with a IC50 value of 2.2 ± 0.05 µM. As the substrate-binding activity of FHIT is essential for its anti-tumor function48, we speculate that STS might mimic the function of Ap3A. Given that FHIT-Ap3A complex was immediately abolished when Ap3A was hydrolyzed48, while STS functions as a nonhydrolyzable substrate, the stabilized FHIT-STS complex could enhance the anti-tumor function of FHIT. In addition, it has been reported that a nonhydrolyzable analog of Ap4A binded to FHIT and stabilized its’ flexible loop which was important for its tumor suppression activity69. Therefore, STS may function in a similar way to enhances the anti-tumor function of FHIT as the nonhydrolyzable substrate. Moreover, pro-apoptotic induction by TSA and TanI’s was partially blocked by FHIT depletion. Considering that FHIT knockout did not fully abolish tanshinones’ anti-cancer function, there should be multiple targets in multiple steps involved to the effects of tanshinones inhibition of tumor progression50. Recently, Li et al reported that TSA docked into the ATP-binding pocket of Aurora B, and was a potential ATP competitive kinase inhibitor61. However, that study lacked evidence of direct binding between TSA and Aurora B kinase. It will be interesting to clarify the engagement between TSA and Aurora B and the potential connection to FHIT in the future work.

We also found that STS and TSA are very different on cytotoxicity for HT116 cells, in that TSA significantly inhibited cell growth at 2 µM, while STS did not show any cytotoxicity even at 100 µM (Fig. S3A), although they are structurally similar and function interchangeable. This was also confirmed by the cloning formation assay, TSA at 1 µM clearly abolished the colony formation of HT116 cells while no effect was detected with STS up to 10 µM (Fig. S3B). This difference is consistent to previous studies, in that Song et al reported that TSA inhibited the proliferation, migration, and invasion of colorectal cancer52; osteosarcoma cells53; non-small cell lung cancer cells54, while few report indicated the anti-cancer activity of STS55. One explanation for this difference could be that the higher lipophilicity of TSA facilitates its uptake by cancer cells56.

Finally, an important finding in our study is that STS inhibits FHIT Ap3A hydrolase activity. Diadenosine polyphosphates (ApnAs) have been proposed to have several intracellular functions as signaling stress responses38. Indeed, Ap3A plays an essential role in platelet regulation, which provides a source of long-lasting ADP at the site of vascular injury27. What’s more, the intracellular concentration of Ap4A increases upon oxidative stressors, and aminoglycoside antibiotics induce the production of Ap4A in bacteria, which in turn enhances their bacterial activity38. In addition, Ap4A attenuates STING-dependent signaling and inflammatory59. Given that tanshinone compounds have similar activities, such as anti-coagulant, anti-oxidant, and anti-inflammatory24, tanshinone compounds directly bind on FHIT ‘active site’ and inhibit its hydrolase activity may shed light on the molecular mechanism of the function for those compounds. The role of FHIT and its hydrolase activity in cardiovascular, ROS, and STING signaling is also worth to be anticipated in future studies.

Materials and methods

Chemicals. Sodium tanshinone IIA sulfonate (STS), Tanshinone IIA (TSA), tanshinone I (TanI), and Cryptotanshinone (CST) are purchased from APEXBio.

Cell culture. The HCT116 CRC cell line is purchased from the American Type Culture Collection (Manassas, VA). HCT116 cells were cultured in RPMI 1640 medium (Thermo Fisher Scientific). The medium was supplemented with 10% fetal bovine serum (FBS) (Gibco, Gaithersburg, MD) and 1% penicillin − streptomycin (HyClone, Logan, UT), and the cell lines were maintained at 37 °C in a humidified atmosphere consisting of 5% CO2 and 95% air.

Protein purification. The gene encoding human FHIT (P49789) was synthesized (Genscript, China) and cloned into pGEX-6P-1 such that the expressed protein would have an N-terminal glutathione S-transferase (GST)-tagged protein. The construct was transformed into expression host E.coli BL21 (DE3), and cells were grown in LB medium at 37 °C until the OD600 reached 0.6. The cells were then induced by adding 0.1 mM isopropyl-β-D-1-thiogalactopyranoside (IPTG) and grown at 18 °C overnight. Cells were harvested by centrifugation, the clarified cell lysate was incubated with glutathione-sepharose 4B beads, and GST-tagged FHIT was eluted with the buffer consisting of 50 mM reduced glutathione. GST tag was cleaved by prescission protease, and the released FHIT was further purified to homogeneity by successive chromatographic steps involving glutathione-sepharose 4B beads, and gel-filtration columns. Pure protein fractions in buffer containing 20 mM Tris (pH 7.5), 150 mM NaCl, and 2 mM DTT were collected and used for the indicated assays. The single-site mutants H96N of FHIT was also constructed in the same vector using two primers, with required mutation using PCR. The mutant was purified with the same protocol as the wild-type FHIT. The gene encoding human HINT1 (P49773), GALT (P07902), DCPS (Q96C86) were synthesized (Genscript, China) and cloned into pET-28a such that the expressed proteins would have an N-terminal 6 × His-tag. Those plasmids were expressed in E. coli BL21(DE3) strain, purified as recommended before, by Co-NTA beads, then size exclusion (Superdex200 increase 10/300GL), and Anion exchange (ENrich Q) columns case by case. Finally, all the proteins were concentrated in 20 mM Tris (pH 7.5), 150 mM NaCl, 2 mM DTT, and stored at – 80 °C.

Microscale thermophoresis (MST). Ten million 293 cells overexpressing GFP-tagged FHIT or free GFP were lysed in 0.5 mL M-PER mammalian protein extraction reagent (Thermo Fisher Scientific). Cell lysates were
diluted in PBS buffer to a final concentration at which the fluorescent signals of the GFP proteins were suitable for the detection of the Monolith NT.115 instrument (NanoTemper Technologies). A single point screening assay was developed against GFP-FHIT protein to find potential binding molecules from compound libraries (L1021, APExBIO). For binding affinity detection, a 10µL protein sample was mixed with 10µL ligand at various concentrations as indicated. And the purified proteins were labeled by Red-NHS kit in accordance with the manufacturer’s protocol (MO-L011, NanoTemper Technologies). Then the mixture solutions were loaded into NT.115 standard coated capillaries or premium coated capillaries (NanoTemper Technologies), and the MST measurements were performed at 25 °C. The fluorescence signal during the thermophoresis was monitored and the change in fluorescence was analyzed by software. The Kd was calculated by fitting a standard binding curve to the series diluted ligands. And data were analyzed by GraphPad Prism 7.0.

**FHIT hydrolase activity detection assay.** 5 nM FHIT protein was mixed with series diluted compounds as indicated in assay buffer (20 mM Tris–HCl, 2 mM DTT, 5 mM MgCl2, pH7.5) in a final DMSO concentration of 1% in a total volume of 20 µL. The mixtures were incubated for 30 min at 25 °C, then 500 nM Ap3A was added. After incubation at 25 °C for 5 min, the production of ADP in the reaction system was detected by ADP-Glo reagent (V6930, Promega) according to the manufacturer’s protocol in 384-well. Luminescence was read by spark (TECAN), an integration time of 1 s per well. And the data were analyzed by GraphPad Prism 7.0.

**Fluorescent thin layer enzyme assay.** Fluorescent substrates ApppBODIPY at 5 µM were incubated with purified Fhit protein 10 nM in reactions at 25 °C containing 20 mM Tris–HCl, pH7.5, 150 mM NaCl, and 5 mM MgCl2. Competitive compounds, when indicated at series concentrations, were mixed with a fluorescent substrate. Reaction samples (0.6µL) were spotted on silica TLC plates (MERCK) at 60–120 s intervals. Plates were air-dried and developed in 2-propanol:NH4OH:1.4-dioxane: H2O (50:35:8:7) as reported before. Developed plates were imaged by fluorescein blot (Chemidoc, Bio-Rad).

**Molecular docking.** To find STS binding site against FHIT, the X-ray crystal structure of FHIT with AMP (PDB ID: 3FIT) was downloaded from Protein Data Bank (PDB). The protein structure was prepared using AutoDockTools-1.5.6, including deleting AMP and water molecules, and adding hydrogens, before the corresponding protein grid files were generated for docking. Then the structure file of STS was pretreated in the Ligand module of AutoDockTools-1.5.6, and docking was performed with AutoDock Vina software as mentioned before. The docking pose for the FHIT–STS complex was then submitted to binding mode analysis and figure generation using PyMOL1.8.

**Fluorescence polarization assay.** The binding of FHIT (H96N) to fluorescein-labeled substrates App-pBODIPY was analyzed by fluorescence polarization assay in 384-well format for dose–response curve studies using spark instrument (TECAN) according to the protocol reported before. And 5 µM FHIT (H96N) protein was incubated with 1 µM fluorescein-labeled substrates in buffer A (25 mM Tris–HCl, pH 7.5, 5 mM MgCl2 and 2 mM DTT) with series diluted inhibitors as indicated. Each sample was allowed to equilibrate in the solution for 30 min. After 30 min, the steady-state fluorescence anisotropy (mP) was measured. A second reading was taken after 10 min, to ensure that the mixture was well-equilibrated and stable. Less than 5% change was observed between 30 and 40 min measurements. The IC50 value was determined by fitting the binding curves using GraphPad Prism 7.0.

**CCK-8 assay for cell inhibitory rate.** The CCK-8 (Cell-Counting Kit-8) assay was used to detect the cells/inhibitory rate following the manufacturer’s protocol (APExBIO). Cells were seeded into 96-well plates at the density of 4 × 10^3 (cells/well) overnight at 37 °C. After that, the culture medium was removed and the cells were treated with different concentrations of TSA (0, 1, 2, 5, 10 µM) or STS (0, 10, 25, 50, 100 µM) for 24 h, 48 h, 72 h respectively. Then 10 µL CCK-8 reagent was added into each well and incubated for another 2 h, OD450 was measured by a microplate reader (spark, TECAN).

**Western Blot analysis.** Cells were lysed using RIPA (Cell Signaling Technology) containing protease inhibitor (Thermo Fisher Scientific) at 4 °C. Proteins were quantified by BCA protein quantification kit (Thermo Fisher Scientific). And proteins (10–30 µg per lane) were separated by SDS-PAGE and then transferred onto polyvinylidene fluoride membranes (Millipore). Following this, the membranes were blocked with 5% non-fat milk for an hour. Later on, the membranes were incubated with primary antibodies anti-FHIT (#ab170888, Abcam), anti-GAPDH (#5174, CST) overnight at 4 °C. After that, the membranes were incubated with HRP-goat anti-mouse secondary antibodies (1:5000, CST) for 1 h, Enhanced chemiluminescence detection reagent (NCM biotech) was used to visualize the signal strength of the bands.

**CRISPR/Cas9 mediated FHIT knockout assay.** FHIT gene was deleted in HCT116 cells by CRISPR/Cas9 genome editing. A plasmid pl-CRISPR.EFS.GFP (#57,818, Addgene) encoding both the Cas9 protein and the sgRNA was used. The Cas9 sequence is coupled to a P2A site and EFGP. Expression of the Cas9 protein results in simultaneous expression of EGFP allowing for the selection of positively transfected cells. Two sgRNA toward exon5 and exon6 of the FHIT gene, respectively, were designed by using the optimized CRISPR design online tool (http://crispr.cox.umi-heidelberg.de). The primers sequences of the sgRNA used were shown as below: sgRNA1 for exon5 forward, 5’CCACCGGTCTCGCTTGGCTTGGTGAAT3’; reverse, 5’AAACATCTCAAGAGCGAA GGACAC3’; sgRNA2 for exon6 forward, 5’CACCAGCCCAAGAGTGGACGACAG3’; reverse, 5’TAAA
CCTGTCCCGACTCTCTGGGTC3'. Plasmids containing the right insertion were then sequenced by Sangon Biotech Company (Shanghai, China). The two CRISPR/Cas9 plasmids were co-transfected into HCT116 cells as 1:1 using Lipofectamine3000 (Invitrogen). After 48 h, EGFP positive single cell was sorted into 96-well plates and the plates were left in the incubator for 7–14 days or until small colonies could be seen by the naked eye. Genomic DNA of each well was extracted by QuickExtract DNA Extraction Solution (Epicenter, Madison, WI) to do PCR identification. And the PCR products were then Sanger-sequenced to identify clones that would result in frameshifts and truncated protein products. Sequence alignment and genomic PCR primers were shown as below: forward, 5'GAATCCATCTCCCCACC3', reverser, 5'CATCACAAAGGCACTC3'.

Apoptosis detection by flow cytometry analyses. HCT116 cells treated with indicated compounds were digested with 0.25% trypsin (Gibco). The cells were harvested by centrifugation at 1000 rpm for 5 min. The trypsinization time should not be too long to prevent false positives. The cells were washed twice with pre-cooled PBS. The cells were resuspended with 1× annexin-binding buffer and the cell density was adjusted to ~ 1 × 10^6 cells/ml. Then 5µL Alexa Fluor 488 annexin V and 1 µL 100 µg/mL PI working solution (V13241, Invitrogen) was added to each 100 µl cell suspension. The cells were incubated at room temperature for the dark for 15 min. After the incubation, 400 µL 1× annexin-binding buffer was added to the cells, mixed gently, and kept the samples on ice. Analyze the stained cells by flow cytometry as soon as possible. The V-FITC positive and PI negative cells were recorded as apoptotic cells.

Statistical analysis. The results are expressed as the mean ± SEM. The data analysis was performed using GraphPad Prism version 7.

Data availability
All data pertinent to this work are contained within this manuscript or available upon request. For request, please contact: Innovation Center of Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, China, xisongke@shutcmedu.cn.

Received: 7 December 2020; Accepted: 17 May 2021
Published online: 09 June 2021

References
1. Ishii, H. Potential cancer therapy with the FHIT gene review of the preclinical studies. JAMA 286, 2441 (2001).
2. Barnes, L. D. et al. Fhit, a putative tumor suppressor in humans, is a dinucleoside 5',5”-P1, P3-triphosphate hydrolase. Biochemistry 35, 11529–11535 (1996).
3. Brenner, C. Purification and crystallization of complexes modeling the active state of the fragile histidine triad protein. Protein Eng. 10, 1461–1463 (1997).
4. Lima, C. D., Klein, M. G. & Hendrickson, W. A. Structure-based analysis of catalysis and substrate definition in the HIT protein family. Science 278, 286–293 (1997).
5. Siprashvlli, Z. Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc. Natl. Acad. Sci. U S A 94, 13771–13776 (1997).
6. Ji, L. et al. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. Cancer Res. 59, 3333–3339 (1999).
7. Pace, H. C. Genetic, biochemical, and crystallographic characterization of Fhit-substrate complexes as the active signaling form of Fhit. Biochem. J. 35, 5484–5489 (1998).
8. Trapasso, F. et al. Designed FHIT alleles establish that Fhit-induced apoptosis in cancer cells is limited by substrate binding. Proc. Natl. Acad. Sci. U S A 100(4), 1592–1597 (2003).
9. Joannes, A. et al. Fhit regulates invasion of lung tumor cells. Oncogene 29(8), 1203–1213 (2010).
10. Joannes, A. et al. Fhit regulates EMT targets through an EGFR/Src/ERK/Slug signaling axis in human bronchial cells. Mol. Cancer Res. 12(5), 775–783 (2014).
11. Suh, S. S. et al. FHIT suppresses epithelial-mesenchymal transition (EMT) and metastasis in lung cancer through modulation of microRNAs. PLoS Genet. 10(10), e1004652 (2014).
12. Nakagawa, Y. & Akao, Y. Fhit protein inhibits cell growth by attenuating the signaling mediated by nuclear factor-kappaB in colon cancer cell lines. Exp. Cell Res. 312(13), 2433–2442 (2006).
13. Jayachandran, G. et al. Fragile histidine triad-mediated tumor suppression of lung cancer by targeting multiple components of the Ras/Rho GTPase molecular switch. Cancer Res. 67(21), 10379–10388 (2007).
14. Waters, C. E. et al. The FHT gene product: Tumor suppressor and genome "caretaker". Cell Mol. Life Sci. 71(23), 4577–4587 (2014).
15. Boylston, J. A. & Brenner, C. A knockdown with smoke model reveals FHIT as a repressor of Heme oxygenase 1. Cell Cycle 13(18), 2913–2930 (2014).
16. Druck, T. et al. Fhit-Fdxr interaction in the mitochondria: modulation of reactive oxygen species generation and apoptosis in cancer cells. Cell Death Dis. 10(3), 147 (2019).
17. Rottläin, P., Rodríguez-Ferrer, C. R., Asensio, A. C. & OAKIN, S. Potent inhibition of specific diadenosine polyphosphate hydrolases by suramin. FEBS Lett. 429, 143–146 (1998).
18. Flores, N. A., Stavrou, B. M. & Sheridan, D. J. The effects of diadenosine polyphosphates on the cardiovascular system. Cardiovasc. Res. 221(2), 15–26 (1999).
19. Hacker, S. M. et al. Selective monitoring of the enzymatic activity of the tumor suppressor Fhit. Angew. Chem. Int. Ed. Engl. 53(38), 10247–10250 (2014).
20. Lange, S. et al. Small-molecule inhibitors of the tumor suppressor Fhit. ChemBioChem 18(17), 1707–1711 (2017).
21. Cui, C. et al. Is beta-catenin a druggable target for cancer therapy?: Trends Biochem. Sci. 43(8), 623–634 (2018).
22. Su, C. Y. et al. Salvia miltiorrhiza: Traditional medicinal uses, chemistry, and pharmacology. Chin. J. Nat. Med. 13(3), 163–182 (2015).
23. Li, Z. et al. Pharmacological basis of tanshinone and new insights into tanshinone as a multitarget natural product for multifaceted diseases. Biomed. Pharmacother 130, 110599 (2020).
24. Jiang, Z., Gao, W. & Huang, L. Tanshinones, Critical Pharmacological Components in Salvia miltiorrhiza. Front Pharmacol 10, 202 (2019).
25. Fang, Z. Y. et al. Tanshinone IIA: A review of its anticancer effects. Front. Pharmacol. https://doi.org/10.3389/fphar.2020.611087 (2021).
26. Shang, Q., Xu, H. & Huang, L. Tanshinone IIA: A promising natural cardioprotective agent. Evid. Based Compl. Altern. Med. 2012, 716459 (2012).
27. Ansari, M. A. et al. Prospective therapeutic potential of Tanshinone IIA: An updated overview. Pharmacol Res. 164, 105364 (2021).
28. Guo, R. et al. Pharmacological activity and mechanism of Tanshinone IIA in related diseases. Drug Des. Dev. Ther. 14, 4735–4748 (2020).
29. Li, M. et al. Tanshinone IIA inhibits oral squamous cell carcinoma via reducing Akt-c-Myc signaling-mediated aerobic glycolysis. Cell Death Dis. 11(5), 381 (2020).
30. He, L. & Gu, K. Tanshinone IIA regulates colorectal cancer apoptosis via attenuation of Parkin-mediated mitophagy by suppressing AMPK/Skp2 pathways. Mol. Med. Rep. 18(2), 1692–1703 (2018).
31. Liao, X. Z. et al. Tanshinone IIA combined with cisplatin synergistically inhibits non-small-cell lung cancer in vitro and in vivo via down-regulating the phosphatidylinositol 3-kinase/Akt signalling pathway. Phytother. Res. 33(9), 2298–2309 (2019).
32. Zhang, Y. et al. Tanshinone IIA induces apoptosis and autophagy in acute monocytic leukemia via downregulation of P13K/Akt pathway. Am. J. Transl. Res. 11(5), 2995–3006 (2019).
33. Therapeutic effect of sodium tanshinone IIA sulfonate in patients with coronary heart disease. A double blind study. Shanghai Cooperative Group for the Study of Tanshinone IIA. J. Trad. Chin. Med. 4(1), 20–24 (1984).
34. Bao, Y. R. et al. Sodium Tanshinone II sulfonate A ameliorates hypoxia-induced pulmonary hypertension. Front. Pharmacol. 11, 687 (2020).
35. Li, X. X. et al. Sodium tanshinone IIA sulfonate ameliorates hepatic steatosis by inhibiting lipogenesis and inflammation. Biomed. Pharmacother. 111, 68–75 (2019).
36. Chen, T. et al. Sodium Tanshinone IIA sulfonate prevents angiostatin II-induced differentiation of human aortal fibroblasts into myofibroblasts. Oxid. Med. Cell Longev. 2018, 6712585 (2018).
37. Han, D. et al. Sodium tanshinone IIA sulfonate protects ARPE-19 cells against oxidative stress by inhibiting autophagy and apoptosis. Sci. Rep. 8(1), 15137 (2018).
38. Zhou, Z. Y. et al. Sodium tanshinone IIA sulfonate: A review of pharmacological activity and pharmacokinetics. Biomed. Pharmacother. 118, 109362 (2019).
39. Wiener, C. J. et al. Protein-binding assays in biological liquids using microscale thermophoresis. Nat. Commun. 1, 100 (2010).
40. Qu, Y. et al. Axitinib blocks Wnt/β-catenin signaling and directs asymmetric cell division in cancer. Proc. Natl. Acad. Sci. U S A 113(33), 9339–9344 (2016).
41. Lima, C. D. et al. MAD analysis of FHIT, a putative human tumor suppressor from the HIT protein family. Structure 5(6), 763–774 (1997).
42. Martin, J., St-Pierre, M. V. & Dufour, J. F. Hit proteins, mitochondria and cancer. Biochim Biophys Acta 1807(6), 626–632 (2011).
43. Albright, R. A. et al. Molecular basis of purineergic signal metabolism by ectonucleotide pyrophosphatase/phosphodiesterases 4 and 1 and implications in stroke. J. Biol. Chem. 289(6), 3294–3306 (2014).
44. Lai, Z. et al. Tanshinones: An update in the medicinal chemistry in recent 5 years. Curr. Med. Chem. 28, 2807–2827 (2020).
45. Draganscu, A. Fhit-nucleotides specificity probed with novel fluorescent and fluorogenic substrates. Biochem. J. 375, 4555–4560 (2000).
46. Fu, L. et al. The Anticancer Properties of Tanshinones and the pharmacological effects of their active ingredients. Front. Pharmacol. https://doi.org/10.3389/fphar.2020.00193 (2020).
47. Ottey, M. et al. Fhit-deficient normal and cancer cells are mitomycin C and UVC resistant. Br. J. Cancer 91(9), 1669–1677 (2004).
48. Karras, J. R., Pausie, C. A. & Huebner, K. Replicative stress and the FHIT gene: Roles in tumor suppression, genome stability and prevention of carcinogenesis. Cancers (Basel) 118, 1–15 (2009).
49. Krakowiak, A. et al. New interactions between tumor suppressor Fhit protein and a nonhydrolyzable analog of its AP4 A substrate. FEBS Lett. 591(3), 548–559 (2017).
50. Li, Z. et al. Pharmacological basis of tanshinone and new insights into tanshinone as a multitarget natural product for multifaceted diseases. Biomed. Pharmacother. 130, 110599 (2020).
51. Li, M. et al. Targeting Aurora B kinase with Tanshinone IIA suppresses tumor growth and overcomes radiosensitivity. Cell Death Dis. https://doi.org/10.1038/s41419-021-03434-z (2021).
52. Song, Q. et al. Tanshinone IIA inhibits epithelial-to-mesenchymal transition through hindering beta-arrestin1-mediated beta-catenin signaling pathway in colorectal cancer. Front. Pharmacol. 11, 386616 (2020).
53. Huang, S. T. et al. Tanshinone IIA induces intrinsic apoptosis in osteosarcoma cells both in vivo and in vitro associated with mitochondrial dysfunction. Sci. Rep. 7, 40382 (2017).
54. Gao, F. et al. Inhibition of EGFR signaling and activation of mitochondrial apoptosis contribute to Tanshinone IIA-mediated tumor suppression in non-small cell lung cancer cells. Onco Targets Ther. 13, 2757–2769 (2020).
55. Liu, M. Z., Huang, Y. S. & Xiao, W. Q. No promoting effects of sodium tanshinone II-A sulfonate on growth and metastasis of Lewis carcinoma. Zhongguo Yao Li Xue Bao 12(6), 534–537 (1991).
56. Sui, H. et al. Tanshinone IIA inhibits β-catenin/VEGF-mediated angiogenesis by targeting TGF-β1 in normal and HIF-1α in hypoxic microenvironments in human colorectal cancer. Cancer Lett. 403, 86–97 (2017).
57. Albright, R. A. et al. NPP4 is a procoagulant enzyme on the surface of vascular endothelium. Blood 120(22), 4432–4440 (2012).
58. Li, X. et al. Alarmones Ap4A is elevated by aminoglycoside antibiotics and enhances their bactericidal activity. Proc. Natl. Acad. Sci. U S A 116(19), 9578–9585 (2019).
59. Guerra, J. et al. Lysyl-tRNA synthetase produces diadenosine tetraphosphate to curb STING-dependent inflammation. Sci. Adv. 6(21), eaax3333 (2020).
60. Trotting, O. & Olson, A. J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31(2), 445–461 (2010).
61. Moerke, N. J. Fluorescence polarization (FP) assays for monitoring peptide-protein or nucleic acid-protein binding. Curr. Protoc. Chem. Biol. 1(1), 1–15 (2009).

Acknowledgements
This work was supported by the Natural Science Foundation of China (Grant Nos. 31800668, 81703757, 81874210, 81874319), the Science and Technology Commission of Shanghai Municipality (18401933500), Shanghai Municipal Education Commission (2019-01-07-00-10-E00072, 2021-01-07-00-10-E00116).

Author contributions
X.Z.: Conceptualization, Methodology, Investigation, Validation, Formal analysis, Writing - Original Draft, Software. Y.P.: Data curation, investigation, data Curation. Y.W.: Validation, Visualization, Investigation. B.W.: Conceptualization, Methodology. Y.Y.: Validation. Y.Q.: Supervision, Funding acquisition. X.K.: Project administration, Writing - Reviewing and Editing, Funding acquisition.
Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-91708-z.

Correspondence and requests for materials should be addressed to Y.Q. or X.K.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021